RSS feed

Media Enquiries

Sharon McHale
Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +613 9389 3425
Mobile: +61 409 978 314
45 Poplar Rd, Parkville
Victoria 3052 Australia

CSL Aquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). More.

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
ISTH Congress

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B. More.

Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D
A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia’s largest biotechnology company. More.

Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012. More.

European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). More.

Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%. More.

CSL Welcomes China Entrepreneur Club Delegation
CSL Limited (ASX:CSL) today welcomed a delegation from the China Entrepreneur Club (CEC), the premier business leader platform in China, to their Broadmeadows site in Melbourne. The visit provided an opportunity to share knowledge, experiences and explore collaborative opportunities. More.

>> Prior Archived Newsroom


Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 3425
Mobile: +61 409 978 314
45 Poplar Rd, Parkville
Victoria 3052

LinkedIn Twitter Facebook Google+